| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8794680 | Ophthalmology Retina | 2018 | 6 Pages |
Abstract
In patients previously treated with ranibizumab or bevacizumab for macular edema due to nonischemic CRVO, aflibercept increased the macular edema free interval. This may help minimize the treatment burden in patients with recurrent macular edema secondary to nonischemic CRVO.
Keywords
PRNIAIETDRSBCVACRVOCStCMEcystoid macular edemastandard deviationCentral retinal vein occlusionbest-corrected visual acuityintravitreal aflibercept injectionTAEearly treatment diabetic retinopathy studytreat and extendpro re nataVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Rahul N. MD, Louis K. MD, PhD, Alok S. MD, James D. MD, Chengqing PhD, Mark R. MD,